Trial · NCT01488578
Results by group43
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 43
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). | Tolterodine Tartrate | 984 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs | With Concomitant Drugs | 3483 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs | Without Concomitant Drugs | 3053 | participants | ||
| Number of Participants Which Was Evaluated as Degree of Satisfaction. | Tolterodine Tartrate | Satisfied | 5609 | participants | |
| Number of Participants Which Was Evaluated as Degree of Satisfaction. | Tolterodine Tartrate | Dissatisfied | 1033 | participants | |
| Number of Participants Which Was Evaluated as Degree of Satisfaction. | Tolterodine Tartrate | Neither of the above | 963 | participants | |
| Number of Participants Which Was Evaluated as Degree of Satisfaction. | Tolterodine Tartrate | Unknown | 175 | participants | |
| Number of Participants With an Investigator's Assessment of Clinical Outcome at End of the Study. | Tolterodine Tartrate | Effective | 6536 | participants | |
| Number of Participants With an Investigator's Assessment of Clinical Outcome at End of the Study. | Tolterodine Tartrate | Not effective | 1244 | participants | |
| Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies | With Non-drug Therapies | 317 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies | Without Non-drug Therapies | 6219 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Gender | Male | 2745 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Gender | Female | 3791 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Complications | With Complications | 3960 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Complications | Without Complications | 2576 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Age | <65 Years | 2060 | participants | ||
| Risk Factors for the Proportion of Responders of Tolterodine-Age | >=65 Years | 4476 | participants | ||
| Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy | With BPH | 319 | participants | ||
| Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy | Without BPH | 130 | participants | ||
| Number of Unlisted Treatment Related Adverse Events (TRAEs)Reported in at Least 5 Participants | Tolterodine Tartrate | Abdominal discomfort | 18 | events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01488578/results